Osteosarcoma is a bone-forming cancer predominantly found in children and adolescents more often than in adults. Osteosarcoma of the gnathic apparatus is relatively rare in the young population, and this condition becomes a concern of clinical dentists for predominantly the middle-aged and aging patient groups. Osteosarcomas are invaded by lymphocytes, which exhibit signs of activation. The immune processes that are engaged within the malignant bone matrix involve the production of cytokines, which regulate the process of apoptotic programed cell death. This paper discusses the mechanisms by which apoptosis of osteosarcoma cells is modulated by the neuroendocrine-immune system, and potential physiological implications.
Get full access to this article
View all access options for this article.
References
1.
Angeli A, Masera RG, Sartori ML, Fortunati N, Racca S, Dovio A, et al. -1999-. Modulation by cytokines of glucocorticoid action. Ann NY Acad Sci876:220–220.
2.
Angeli A, Dovio A, Sartori ML, Masera RG, Ceoloni B, Prolo P, et al. -2002-. Interactions between glucocorticoids and cytokines in the bone microenvironment. Ann NY Acad Sci966:97–107.
3.
Bacci G, Ferrari S, Bertoni F, Ruggieri P, Picci P, Longhi A, et al. -2000-. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol18:4016–4027.
4.
Ben-Efraim S -1996-. Cancer immunotherapy: hopes and pitfalls: a review. Anticancer Res16:3235–3240.
5.
Bielack SS, Kempf-Bielack D, Heise U, Schwenzer D, Winkler K -1999-. Combined modality for osteosarcoma occurring as a second malignant disease. Cooperative German-Austrian-Swiss Osteosarcoma Study Group. J Clin Oncol17:1164.
6.
Bieling P, Rehan N, Winkler P, Helmke K, Maas R, Fuchs N, et al. -1996-. Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol14:848–858.
7.
Chen YB, Hahn LJ, Yao YT -1999-. Long-term survival of patients with mandibular osteosarcoma. J Formos Med Assoc98:773–777.
8.
Chiappelli F, Liu QN -1999-. Non-mammalian models of neuroendocrine-immune modulation. Relevance for research in oral biology and medicine. Int J Oral Biol24:47–61.
9.
Chiappelli F, Manfrini E, Franceschi C, Cossarizza A, Black KL -1994-. Steroid regulation of cytokines. Relevance for TH1-to-TH2 shift? Ann NY Acad Sci746:204–215.
10.
Chiappelli F, Abanomy A, Hodgson D, Mazey KA, Messadi DV, Mito RS, et al. -2001a-. Clinical, experimental and translational psychoneuroimmunology research models in oral biology and medicine. In: Psychoneuroimmunology. Vol. III. Ader R, Felten D, Cohen N, editors. Chapter 64. New York: Academic Press, pp. 645-670.
11.
Chiappelli F, Twu CS, Prolo P, Sartori ML, Masera RG, Staurenghi A, et al. -2001b-. Endocrine-immune modulation of proliferation and apoptosis in osteosarcoma Saos-2 cells. Milan, Italy: 10th Annual Congress of the European Association for Osseointegration.
12.
Chiappelli F, Prolo P, Rosso MG, Mondino F, Dovio A, Sartori ML, et al. -2002-. Cellular immune toxicity of the amyloid-β protein and its fragments in human lymphoid cells: implications for immune mediated processes in Alzheimer’s disease. 8th Alzheimer’s Association International Conference, Stockholm, Sweden, July 20-25, 2002.
13.
Clark JL, Unni KK, Dahlin DC, Devine KD -1983-. Osteosarcoma of the jaw. Cancer51:2311–2316.
14.
Delgado M, Ganea D -2000a-. VIP and PACAP inhibit activation induced apoptosis in T lymphocytes. Ann NY Acad Sci921:55–67.
15.
Delgado M, Ganea D -2000b-. Vasoactive intestinal peptide and pituitary adenylate cyclaseactivating polypeptide inhibit T cell-mediated cytotoxicity by inhibiting Fas ligand expression. J Immunol165:114–123.
16.
Dovio A, Sartori ML, Masera RG, Racca S, Angeli A -2001-. Inhibitory effect of physiological concentrations of cortisol but not estradiol on interleukin -IL--6 production by human osteoblast-like cell lines with different constitutive IL-6 expression. Cytokine15:47–52.
17.
Fellenberg J, Mau H, Nedel S, Ewerbeck V, Debatin KM -2000-. Drug-induced apoptosis in osteosarcoma cell lines is mediated by caspase activation independent of CD95-receptor/ligand interaction. J Orthop Res18:10–17.
18.
Gallaher BW, Berthold A, Klammt J, Knüpfer M, Kratzsch J, Bartsch M, et al. -2000-. Expression of apoptosis and cell cycle related genes in proliferating and colcemid arrested cells of divergent lineage. Cell Mol Biol46:79–88.
19.
Hengartner MO -2000-. The biochemistry of apoptosis. Nature407:770–776.
20.
Ioannides CG, Whiteside TL -1993-. T cell recognition of human tumors: implications for molecular immunotherapy of cancer. Clin Immunol Immunopathol66:91–106.
21.
Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. -1999-. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature402:304–309.
22.
Kushlinskii NE, Solov’ev YN, Babkina IV, Abbasova SG, Kostanyan IA, Lipkin VM, et al. -2000-. Leptin and apoptosis inhibitor soluble Fas antigen in the serum of patients with osteosarcoma and neuroectodermal bone tumors. Bull Exp Biol Med129:496–498.
23.
Ladizesky MG, Cutrera RA, Boggio V, Mautalen C, Cardinali DP -2000-. Effect of unilateral superior ganglionectomy on bone mineral content and density of rat’s mandible. J Auton Nerv Syst78:113–116.
24.
Masera RG, Dovio A, Sartori ML, Racca S, Angeli A -2000-. Interleukin-6 upregulates glucocorticoid receptor numbers in human osteoblast-like cells. Z Rheumatol59:103–107.
25.
Murphey MD, Robbin MR, McRae GA, Flemming DJ, Temple HT, Kransdorf MJ -1997-. The many faces of osteosarcoma. Radiographics17:1205–1231.
26.
Odell PF -1996-. Head and neck sarcomas: a review. J Otolaryngol25:7–13.
27.
Prolo P, Wong ML, Licinio J -1998-. Leptin. Int J Biochem Cell Biol30:1285–1290.
28.
Prolo P, Chiappelli F, Cajulis E, Bauer J, Spackman S, Romeo H, et al. -2002-. Psychoneuroimmunology in oral biology and medicine: the model of oral lichen planus. Ann NY Acad Sci966:429–440.
29.
Romeo HE, Tio DL, Rahman SU, Chiappelli F, Taylor AN -2001-. The glossopharyngeal nerve as a novel pathway in immune-to-brain communication: relevance to neuroimmune surveillance of the oral cavity. J Neuroimmunol115:91–100.
30.
Sartori ML, Masera RG, Staurenghi A, Racca S, Angeli A -1998-. Interleukin 2 up-regulates glucocorticoid receptor number in human peripheral blood mononuclear cells and the osteosarcoma cell line Saos-2 in vitro. Steroids63:349–351.
31.
Schajowicz F, Sissons HA, Sobin LH -1995-. The World Health Organization’s histologic classification of bone tumors. A commentary on the second edition. Cancer75:1208-1214.
32.
Seki K, Yoshikawa H, Shiiki K, Hamada Y, Akamatsu N, Tasaka K -2000-. Cisplatin -CDDP- specifically induces apoptosis via sequential activation of caspase-8, -3 and -6 in osteosarcoma. Cancer Chemother Pharmacol45:199–206.
33.
Smeele LE, Kostense PJ, van der Waal I, Snow GB -1997-. Effect of chemotherapy on survival of craniofacial osteosarcoma: a systematic review of 201 patients. J Clin Oncol15:363–367.
34.
Swolin D, Ohlsson C -1996-. Growth hormone increases interleukin-6 produced by human osteoblast-like cells. J Clin Endocrinol Metab81:4329–4333.
35.
Swolin-Eide D, Ohlsson C -1998-. Effects of cortisol on the expression of interleukin-6 and interleukin-1beta in human osteoblast-like cells. J Endocrinol156:107–114.
36.
Tarozzi A, Mariani E, Facchini A -1995-. In vitro cytolytic activity of human NK cells against osteosarcoma cell lines. Boll Soc Ital Biol Sper71:221–226.
37.
Trieb K, Lechleitner T, Lang S, Windhager R, Kotz R, Dirnhofer S -1998-. Evaluation of HLA-DR expression and T-lymphocyte infiltration in osteosarcoma. Pathol Res Pract194:679–684.
38.
Vidal ON, Sjogren K, Eriksson BI, Ljunggren O, Ohlsson C -1998-. Osteoprotegerin mRNA is increased by interleukin-1 alpha in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells. Biochem Biophys Res Commun248:696–700.
